Posted from: Thursday, March 07, 2019 - 10:32 AM - Present

Praluent List Price Reduced by 60%

February 11, 2019 – Sanofi and Regeneron have announced plans to reduce the list price for Praluent® (alirocumab), a PCSK9 inhibitor, to $5,850 per year. The 60% reduction from the drug’s original list price will go into effect in March and apply to both the 75mg and 150mg dosage strengths.

According to a press release, Sanofi and Regeneron anticipate the new price to improve affordability and access for patients. PCSK9 inhibitors, which include Praluent and Amgen’s Repatha® (evolocumab), have drawn criticism for high list prices in the past. Both were originally priced at $14,000 per year (list price), a number that the Institute for Clinical and Economic Review (ICER) deemed to not be cost-effective. In October 2018, Amgen was the first company to reduce its PCSK9 inhibitor’s list price to $5,850 per year.

The changes in list price for Praluent and Repatha may have the most immediate impact on patients who must pay list price for their medications or a percentage copay based on list price. Copay assistance is available for Praluent through the MyPraluent® program and for Repatha through Amgen’s RepathaReady® program.

Although both Praluent and Repatha are indicated to lower high LDL cholesterol, Repatha is indicated for use in a broader patient population, and is also indicated to reduce the risk of heart attack, stroke, and coronary revascularization in adults who have established cardiovascular disease.

Last Updated Tuesday, May 21, 2019 - 05:57 AM.